The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Open accessAbstract
Ketamine, a racemic mixture of (S)-ketamine and (R)-ketamine enantiomers, has been used as an anesthetic, analgesic and more recently, as an antidepressant. However, ketamine has known abuse liability (the tendency of a drug to be used in non-medical situations due to its psychoactive effects), which raises concerns for its therapeutic use. (S)-ketamine was recently approved by the United States' FDA for treatment-resistant depression. Recent studies showed that (R)-ketamine has greater efficacy than (S)-ketamine in preclinical models of depression, but its clinical antidepressant efficacy has not been established. The behavioral effects of racemic ketamine have been studied extensively in preclinical models predictive of abuse liability in humans (self-administration and conditioned place preference [CPP]). In contrast, the behavioral effects of each enantiomer in these models are unknown. We show here that in the intravenous drug self-administration model, the gold standard procedure to assess potential abuse liability of drugs in humans, rats self-administered (S)-ketamine but not (R)-ketamine. Subanesthetic, antidepressant-like doses of (S)-ketamine, but not of (R)-ketamine, induced locomotor activity (in an opioid receptor-dependent manner), induced psychomotor sensitization, induced CPP in mice, and selectively increased metabolic activity and dopamine tone in medial prefrontal cortex (mPFC) of rats. Pharmacological screening across thousands of human proteins and at biological targets known to interact with ketamine yielded divergent binding and functional enantiomer profiles, including selective mu and kappa opioid receptor activation by (S)-ketamine in mPFC. Our results demonstrate divergence in the pharmacological, functional, and behavioral effects of ketamine enantiomers, and suggest that racemic ketamine's abuse liability in humans is primarily due to the pharmacological effects of its (S)-enantiomer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, similar range of affinity values at μ and κ opioid receptors were recently reported for (S)-ketamine (μ: Ki = 7 μM and κ: Ki = 19 μM) and (R)-ketamine (μ: Ki = 14 μM and κ: Ki = 40 μM) (Bonaventura et al.,”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this study’s main findings rely on computational analysis and the predicted affinity and G protein recruitment values it reports are not consistent with several prior publications (Bonaventura et al., 2021; Hirota et al., 1999; Nemeth et al., 2010).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“conditioned lever responding for (S)-ketamine is rapidly extinguished with fewer than 10 responses over three hours on the first extinction training day”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, (S) and (R)-ketamine have agonist properties at μ and κ opioid receptors, an interaction which may be necessary for their antidepressant effects (Bonaventura et al., 2021).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence suggests that ketamine therapy may be associated with certain risks, such as increasing drug-dependence-related behaviors like self-administration, conditioned place preference, hyperlocomotion, and prepulse inhibition deficits [155-157]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [155]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinically, (R)-ketamine does not induce conditioned place preference, deficits in prepulse inhibition, or hyperlocomotion [155-157]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [155]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“(S)-ketamine induces conditioned place preference in mice and conditioned operant lever responding for an infusion in rats whereas (R)-ketamine largely does not”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“this study showed that (S)-ketamine acted as a partial G protein signaling agonist at μ opioid receptors (EC50 = 9 μM, Emax = 48%) and as a full agonist at κ opioid receptors (EC50 = 16 μM, Emax = 84 %)”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, neither enantiomer activated ß-arrestin.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“whereas (R)-ketamine acted as a weak partial agonist at both μ opioid receptors (EC50 = 34 μM, Emax = 39 %) and κ opioid receptors (EC50 > 100 μM, Emax < 50%).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Intriguingly, (R) and (S)-ketamine appear to have agonist properties at μ and κ opioid receptors, with (S)-ketamine having a higher affinity”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationA psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Kalivas, P., & Stewart, J. (1991) · Brain research. Brain research reviews · doi:10.1016/0165-0173(91)90007-u · Cited by 2,087
Wise, R. A., & Rompre, P.-P. (1989) · Annual Review of Psychology · doi:10.1146/annurev.ps.40.020189.001203 · Cited by 1,968
Opioids excite dopamine neurons by hyperpolarization of local interneurons
Johnson, S., & North, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00483.1992 · Cited by 1,637
Richardson, N. R., & Roberts, D. C. S. (1996) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(95)00153-0 · Cited by 1,373
Conditioned place preference: what does it add to our preclinical understanding of drug reward?
Bardo, M. T., & Bevins, R. A. (2000) · Psychopharmacology · doi:10.1007/s002130000569 · Cited by 1,274
Cited by
Sorted by citations
Items 201–270 of 270
Seta, R. R., Mahabadi, S. E., Delphi, L., Alijanpour, S., & Rezayof, A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.067 · Cited by 2
de Miranda, A. S., Toscano, E. C. D. B., Venna, V. R., Graeff, F. G., & Teixeira, A. L. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2460674 · Cited by 3
N-Ethylnorketamine has anesthetic and analgesic effects with abuse liability
Li, F., Qiao, Y., Chen, Y., Li, N., Yang, M., Li, X., Qiu, Y., Cui, W., Shen, H., Xu, P., et al. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114052 · Cited by 2
In vivo photopharmacology with light-activated opioid drugsPreprint
McClain, S. P., Ma, X., Johnson, D. A., Johnson, C. A., Layden, A. E., Yung, J. C., Lubejko, S. T., Livrizzi, G., He, X. J., Zhou, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.02.526901 · Cited by 2
Self-citationFrom psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Regen, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_1 · Cited by 1
Asrar, B., Metin, S., Sen, Z., & Ünal, G. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110650 · Cited by 1
Advances in sample pretreatment for the analysis of ketamine and its analogs: A review
Qian, M., Liu, J.-X., Zhang, Y., Wang, M.-D., Shao, W. Y., Wang, Y., & Feng, X. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.117012 · Cited by 1
Lee, C.-H. J., Qian, Y., Yu, W., Cusin, C., & Sheng‐Kai, K. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121487 · Cited by 1
Regen, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_1 · Cited by 1
Bartas, K., Derdeyn, P., Tian, G., Vasquez, J. J., Azouz, G., Yamamoto, C. M., Hui, M., & Beier, K. T. (2026) · eLife · doi:10.7554/elife.93664.3 · Cited by 2
Kétamine et suicidalité : modèles animaux pour comprendre son mécanisme d’action
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2023.10.008 · Cited by 2
Yahyaei, B., Gholipour, F., Khojasteh, L., Hakimabadi, M. G., Feyzabadi, F. B., Dankoub, F., & Nasehi, M. (2024) · ماهنامه علمی پژوهشی دانشگاه علوم پزشکی شهید صدوقی یزد · doi:10.18502/ssu.v32i5.16121 · Cited by 1
Kalkman, H. O., & Smigielski, L. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70019 · Cited by 1
Bonaventura, J., Lam, S., Carlton, M. L., Boehm, M. A., Gomez, J. L., Solís, Ó., Sánchez‐Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01666-9 · Cited by 1
Self-citationMichaelides, M., Levinstein, M. R., Oliveira, P. D., Casajuana-Martín, N., Quiroz, C., Budinich, R. C., Rais, R., Rea, W. P., Ventriglia, E. N., Llopart, N., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2644719/v1 · Cited by 1
Self-citationPomrenze, M. B., Vaillancourt, S., Llorach, P., Rijsketic, D. R., Casey, A. B., Gregory, N. S., Salgado, J. S., Malenka, R. C., & Heifets, B. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.03.583196 · Cited by 1
Jornet-Plaza, J., Ledesma‐Corvi, S., & García-Fuster, M. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.08.622617 · Cited by 1
Daher, F., Fukushima, C. T., Ingebretsen, E. A., Bidlack, J. M., Atack, J. R., Popa, M. O., & Fogaça, M. V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.15.699507 · Cited by 1
Kvarta, M. D., & Zarate, C. A. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260266 · Cited by 1
Self-citation(R)-Ketamine: A New Rapid-Acting Antidepressant
Zhang, K., & Hashimoto, K. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_1
Artin, H., Bentley, S., Mehaffey, E., Liu, F. X., Sojourner, K., Bismark, A. W., PRINTZ, D. J., Lee, E., Martis, B., Peralta, S. D., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3928508
Alan F. Schatzberg, MD, on the state of psychiatry
Aftab, A. (2022) · Current Psychiatry · doi:10.12788/cp.0202
Oemisch, M., & Seo, H. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.25.501468
Javitt, D. C., & Javitt, J. C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.12.503713
Antidepressants and memory effects of ketamine under the neuromolecular view: A literature review
da Silva, F. P. G., Gabriel Rezende, M., Scapatici, L. P., Zanelatto, D. A. L., Lombardi, B. C., Vidal, C., Wiedmer, D. B., Lucas, S., Minhoto, G. R., & Andreatini, R. (2023) · Archives of Depression and Anxiety · doi:10.17352/2455-5460.000073
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making
Oemisch, M., & Seo, H. (2023) · eLife · doi:10.7554/elife.87529 · Cited by 2
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-makingPreprint
Oemisch, M., & Seo, H. (2023) · eLife · doi:10.7554/elife.87529.1
Neurobiological Foundations of Mood Disorders
Manchia, M., & Schatzberg, A. F. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_83-1
Sex Differences in the Antidepressant Effects of Ketamine
Myers, M. (2023) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2023-15485
Kasai, A., Yokoyama, R., Ago, Y., Igarashi, H., Higuchi, M., Tanuma, M., Shimazaki, Y., Seiriki, K., Hayashida, M., Yamaguchi, S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3305430/v1
Tanggung Gugat Marketplace Sebagai Penyedia Layanan Dompet Digital (Shopee-Pay) Terhadap Konsumen
Nelly Zinnani, F. A., & Suryono, A. (2023) · Indonesian Journal of Law and Justice · doi:10.47134/ijlj.v1i2.2036
Laely, S. F., & Iman, M. K. (2023) · Indonesian Journal of Law and Justice · doi:10.47134/ijlj.v1i2.2037
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-makingPreprint
Oemisch, M., & Seo, H. (2024) · eLife · doi:10.7554/elife.87529.2
Bartas, K., Derdeyn, P., Tian, G., Vasquez, J. J., Azouz, G., Yamamoto, C. M., Hui, M., & Beier, K. T. (2024) · eLife · doi:10.7554/elife.93664
Bartas, K., Hui, M., Derdeyn, P., Tian, G., Vasquez, J. J., Azouz, G., Yamamoto, C. M., & Beier, K. T. (2024) · eLife · doi:10.7554/elife.93664.1
Multimodal Analgesia for Complex Spine Surgeries
Farag, E. S. (2024) · Topics in Pain Management · doi:10.1097/01.tpm.0001012648.29185.17
Pham, G. S., & Mathew, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00014-8
Are ketamine and its enantiomers the answer to treatment-refractory depression?
Belge, J.-B., Scantamburlo, G., & Constant, E. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2373302
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd03
Chapter 10. Emergency Department Treatment
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd10
Research Progress of Esketamine in Improving Perioperative Depression and Sleep Quality
高, 永. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1472116
Pulido-Saavedra, A., Borelli, A., Kitaneh, R., Alrafayia, M., Khave, L. J., Funaro, M. C., Potenza, M. N., & Angarita, G. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2446623
Arketamine: Unapproved but Promising Antidepressant with Multiple Brain Benefits
Wan, X., & Hashimoto, K. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_15
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Preclinical Studies on Ketamine and Its Enantiomers with Translational Significance
Elersič, K. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_5
Ketamine for neuropathic pain: Animal and human studies
Dahan, A., Niesters, M., Sarton, E. Y., & van Velzen, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00016-3
Resurgence of N-Methyl-d-Aspartate Receptor (NMDAR) Antagonists in Perioperative Medicine
Farag, E. S., Soliman, N., & Seif, J. (2025) · Topics in Pain Management · doi:10.1097/01.tpm.0001169656.75858.7a
Liu, J., Liang, Z., Wang, H., Chen, S., Xie, Y., Xing, F., Wang, Z., Yang, J., & Yuan, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s562398 · Cited by 1
Xie, J.-X., & Zhou, L.-W. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11357-7
Bartas, K., Derdeyn, P., Tian, G., Vasquez, J. J., Azouz, G., Yamamoto, C. M., Hui, M., & Beier, K. T. (2026) · eLife · doi:10.7554/elife.93664.2
Disruption of psychostimulant-associated memories by single, low dose ketamine in rats
Gonzalez, A. E., Ramos, J. D., Anderson, Z., Sewell, C. M., Modaberi, S., Hentges, S. T., Brown, T. E., & Sorg, B. A. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110912
Comparative EEG analysis of the effects of ketamine enantiomers and metabolites in rhesus macaques
Iwamura, Y., Nishigori, K., Yamaguchi, M., Ogi, Y., Kobayashi, A., Iwasaki, T., Nagata, H., & Ikeda, K. (2026) · Journal of Neurophysiology · doi:10.1152/jn.00203.2025 · Cited by 1
Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.
Schatzberg, A. F., & Fountoulakis, K. Ν. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260182
Xiong, H., Xu, Y., Liu, J., Liu, G., Zhang, Y., Wei, Z., Liang, W., Zhao, X., Li, S., Xiao, G., et al. (2026) · Clinics · doi:10.1016/j.clinsp.2026.100921
Serotonergic and glutamatergic mechanisms converge in ketamine’s rapid responses
Fogaça, M. V. (2026) · Trends in Neurosciences · doi:10.1016/j.tins.2026.03.010
Qasim, R., Mehmood, H., Raza, M., Tariq, Z., Mohib, K., Haseeb, B., Ahmed, A.-B., Hussain, A. A., Shakeel, I., Aminpoor, H., et al. (2026) · European Journal of Anaesthesiology Intensive Care · doi:10.1097/ea9.0000000000000103
Roelandt, G. H. J., Strous, J. F. M., Kamphuis, J., Schoevers, R. A., & Marijnissen, R. M. (2026) · BJPsych Open · doi:10.1192/bjo.2026.11012
Yang, S., Wang, L. J., Sun, Y., Ma, X. Y., Rong, Y., Fong, T. H., Li, T., Deng, D., Li, X.-X., Zhang, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.31.727553
Chen, Z., Wang, Y., Cong, P., Wang, L., Sun, P., Li, Z. Y., Zhang, H., Li, G., Jiao, F., Zhao, J., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2692804
Treating addiction with an addictive drug: the ketamine paradox revisited
Hakami, A. Y. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1866092
Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report
Rosal, S. P., Faber, S. C., & Backmund, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1846320
The functional role of ERK activity in esketamine's antidepressant effects
Zhang, P. X., Wu, M., Zhang, K., He, J., Liu, X., Zhang, H., Hu, A. Z., & Zhou, W. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174248
Molecular snapshots confirm ketamine’s opioid nature
Bonaventura, J., & Michaelides, M. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01874-9
Self-citationD’Ottavio, G., Sullivan, A., Pilz, E. M., Schoenborn, I., Solís, Ó., Gomez, J. L., Kahnt, T., Michaelides, M., & Shaham, Y. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2610087123
Self-citationTao, M., Li, Y., Chen, W., Zang, H., Wang, Q., Wang, Q., Wang, Y., Huang, C., Zou, H., & Zhen, S. (2026) · Journal of Analysis and Testing · doi:10.1007/s41664-026-00482-2
Is (S)-norketamine an active mediator of esketamine’s antidepressant effects?
Hashimoto, K., & Yang, C. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03867-y
Dawoud, A. M., Gupta, A., Gomes, I., Baker, D., Shapiro, J. E., Devi, L., Hurd, Y. L., & Osman, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.01.748554
Malewska-Kasprzak, M., Rybakowski, F., & Dmitrzak‐Węglarz, M. (2026) · CNS Spectrums · doi:10.1017/s1092852926101187
Sulej, Z., & Zielińska, M. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1950244
Metadata
- Authors
- Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., Sibley, D. R., Shaham, Y., Zarate, C. A., & Michaelides, M.
- Affiliations
- National Institutes of Health (US)
- National Institute on Drug Abuse (US)
- National Center for Advancing Translational Sciences (US)
- National Institute of Neurological Disorders and Stroke (US)
- National Institute of Mental Health (US)
- Corresponding author
- Bonaventura, Jordi
- Michaelides, Michael
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-04-15
- Volume
- 26
- Issue
- 11
- Pages
- 6704-6722
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8517038
- OpenAlex
- W3156594315
- Cited by
- 271
- References
- 86
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 64 · 2023: 56 · 2022: 53 · 2021: 17
- FWCI
- 27.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA000069)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, enantiomers, esketamine, (R)-ketamine, abuse liability, self-administration, conditioned place preference, locomotor activity, locomotor sensitization, medial prefrontal cortex, dopamine, opioid receptors, mu-opioid receptor, kappa opioid receptor, antidepressant efficacy, treatment-resistant depression
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Stereoisomerism, Mice, Rats, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
